Omoprubart

欧莫扑拜单抗

Report date: 2023/12/29 11:51:50

Base Information

Drug NameOmoprubart
Drug Alias NameCAN-106
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionComplement C5 inhibitors
TargetsComplement C5
Therapy Area/IndicationsGenetic Diseases, InbornHemoglobinuria, Paroxysmal
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySingaporeMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesBeihai Kangcheng (Beijing) Pharmaceutical Technology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesCare Pharma Shanghai LtdCanbridge Life Sciences LtdNuoai Pharmaceutical (Shanghai) Co Ltd
Inactive CompaniesBeihai Kangcheng (Beijing) Pharmaceutical Technology Co LtdWuxi Biologics Co Ltd
Active IndicationsHemoglobinuria, Paroxysmal
Inactive IndicationsGenetic Diseases, Inborn

Other Information

ATC CodeN/A
Related LinksN/A